With Merck’s disclosure that they are going to seek approval from the regulatory authorities for a medicine intended to be used in treating cancer when Bristol-Myers have ended a late-stage study of their drug brought the surface the long rivalry again. The insight The moves to get regulatory approvals for new medicines indicate the vehement endeavors the pharmaceutical industry has made to open new vistas to fight the battle against cancer. As revealed by confidential sources in the industry the pharma researchers are at present working round the clock to develop a treatment regime that will stimulate the immune system of the body to combat with tumors and will add billions of dollars revenue annually. The R&D wing of both Merck and Bristol-Myers are working on PD-1 inhibitors that play very important role in streamlining the immune system by preventing the T-cells from activating and thus promoting self tolerance. And these giants hope that such medicines will be extremely usefu
http://cancerinlungs.com/pharma-giants-never-ending-rivalry-heats/
No comments:
Post a Comment